Brief: TOT Biopharm International Gets Marketing Approval For Pusintin From NMPA
01/12/2021 07:59
Dec 1 (Reuters) - TOT BIOPHARM International Co Ltd
1875.HK :
* MARKETING APPROVAL FOR PUSINTIN (TAB008, BEVACIZUMAB
INJECTION,
PUSINTIN) OBTAINED FROM NMPA
Source text for Eikon: ID:nHKS316NTt
Further company coverage: 1875.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioDlink International
See all newsCorrected: China's BioDlink International HY revenue falls (September 29)
Brief: Biodlink International To Deliver Ten Batches Of Monoclonal Antibody Intermediates To Wuxi Biologics
Brief: Biodlink International Says Shan Fu Resigns As Executive Director And Chairperson
Brief: BioDlink International Says WuXi XDC Cayman To Make Conditional Cash Offer For All Co Shares
Brief: HKEX Says Trading In Shares Of Biodlink International Will Be Halted At Dec 29